Pharming Group N.V. (PHAR)

NL — Healthcare Sector
Peers: PHGUF  PRTC  ETON  GNTA  PHVS  NBTX  PHAT  SLN 

Automate Your Wheel Strategy on PHAR

With Tiblio's Option Bot, you can configure your own wheel strategy including PHAR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PHAR
  • Rev/Share 0.5129
  • Book/Share 0.3601
  • PB 3.4017
  • Debt/Equity 0.5357
  • CurrentRatio 2.7948
  • ROIC -0.0954

 

  • MktCap 839306300.0
  • FreeCF/Share 0.0463
  • PFCF 27.2472
  • PE -98.9398
  • Debt/Assets 0.2876
  • DivYield 0
  • ROE -0.0366

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PHAR Jefferies -- Buy -- $14 Dec. 9, 2024

News

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
PHAR, PHGUF
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral

Pharming Group N.V. (NASDAQ:PHAR ) Q2 2025 Earnings Conference Call July 31, 2025 7:30 AM ET Executives Anurag Relan – Chief Medical Officer Fabrice Chouraqui – CEO & Executive Director Stephen Toor – Chief Commercial Officer & GM Americas Analysts Benjamin Jackson - Jefferies Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Simon Scholes - First Berlin Equity Research GmbH Sushila Hernandez - Kempen & Co Fabrice Chouraqui Good morning or good afternoon, everyone, and welcome to our Q2 2025 earnings call.

Read More
image for news Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Best Momentum Stocks to Buy for July 25th
AMZN, PHAR, RVLV
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive

RVLV, PHAR and AMZN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 25, 2025.

Read More
image for news Best Momentum Stocks to Buy for July 25th
Best Momentum Stocks to Buy for July 17th
PHAR, PROK, ROKU
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive

PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.

Read More
image for news Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
KRP, MAG, PHAR, PROK, ROKU
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive

PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.

Read More
image for news New Strong Buy Stocks for July 17th
Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
PHAR, PHGUF
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral

Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Joe Pantginis - H.C.

Read More
image for news Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
PHAR
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.

Read More
image for news Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

About Pharming Group N.V. (PHAR)

  • IPO Date 2020-12-23
  • Website https://www.pharming.com
  • Industry Biotechnology
  • CEO Fabrice Chouraqui
  • Employees 404

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.